Table 2 Complete remission analysis.
Variable | N (%) | CR–CRi (%) | p-value (univariate) | Hazard ratio (95% CI)* | p-value (multiv.) |
|---|---|---|---|---|---|
Overall | 71 (100%) | 50 (70.4%) | – | – | – |
Age | |||||
<70 years | 51 (71.8) | 37 (72.5) | 0.531 | 0.901 (0.639–1.271) | – |
>70 years | 20 (28.2) | 13 (65.0) | |||
Sex | |||||
Male | 39 (54.9) | 29 (74.4) | 0.446 | 0.821 (0.495–1.363) | – |
Female | 32 (45.1) | 21 (65.6) | |||
WBC | |||||
<30 × 109/L | 60 (84.5) | 42 (70.0) | 1.000 | 1.020 (0.825–1.262) | – |
>30 × 109/L | 11 (15.5) | 8 (72.7) | |||
Marrow blasts | |||||
<30% | 22 (31.0) | 19 (86.4) | 0.055 | 0.376 (0.124–1.136) | 0.062 |
>30% | 49 (69.0) | 31 (63.3) | |||
Previous HMA | |||||
No | 54 (76.1) | 40 (74.1) | 0.361 | 0.833 (0.598–1.162) | – |
Yes | 17 (23.9) | 10 (58.8) | |||
NPM1 | |||||
Wild type | 63 (92.6) | 42 (66.7) | 0.176 | 1.194 (1.012–1.235) | 0.150 |
Mutated | 5 (7.4) | 5 (100) | |||
FLT3-ITD | |||||
Negative | 64 (92.8) | 45 (70.3) | 1.000 | 0.965 (0.825–1.119) | – |
Positive | 5 (7.2) | 3 (60.0) | |||
TP53 | |||||
Wild type | 24 (64.9) | 18 (75.0) | 1.000 | 1.037 (0.605–1.776) | – |
Mutated | 13 (35.1) | 10 (76.9) | |||
Karyotype | |||||
Fav./Int. | 39 (54.9) | 31 (79.5) | 0.074 | 0.614 (0.342–1.105) | 0.057 |
Poor | 32 (45.1) | 19 (59.4) | |||
Therapy related | |||||
No | 49 (69.0) | 37 (75.5) | 0.260 | 0.752 (0.515–1.158) | – |
Yes | 22 (31.0) | 13 (59.1) | |||
ELN 2017 | |||||
Low/Int. | 32 (45.1) | 25 (78.1) | 0.296 | 0.667 (0.343–1.297) | – |
High | 39 (54.9) | 25 (64.1) | |||
